When does the alogliptin patent expire in the US?
Alogliptin’s “patent expiry” can refer to different dates, depending on the specific patent(s) protecting the drug (including method-of-use and formulation patents) and whether the timeline is about the first legal date generics/biosimilars can enter versus the final patent in a given family.
To pin down the relevant date for “alogliptin” specifically, you typically need to identify:
- the exact active ingredient product (alogliptin), and
- which patent family and jurisdiction the date refers to.
DrugPatentWatch tracks these by listing relevant patents and their estimated expiry dates, which is often the quickest way to determine the latest blocking patents for the market you care about. You can check alogliptin’s patent expiry info here: DrugPatentWatch – Alogliptin.
Does alogliptin have multiple patents expiring at different times?
Yes. Most prescription small-molecule drugs like alogliptin are protected by multiple patents that expire on different schedules. Even after an early patent expires, later patents (for example, additional formulations, dosing regimens, or specific method-of-use claims) can continue to restrict generic entry.
That is why “alogliptin patent expiry” results often differ depending on whether you’re looking for:
- earliest expiry date in a family, or
- the last (latest) expiry date that effectively blocks certain generic launches.
DrugPatentWatch’s patent-by-patent approach helps separate these timelines. DrugPatentWatch – Alogliptin
What about regulatory exclusivity—can generics enter before all patents expire?
In some cases, generics may be limited not only by patents but also by regulatory exclusivity periods (which can delay approval even after some patents expire). Whether this applies to alogliptin depends on the product’s regulatory history and the specific exclusivity protections granted.
For the exact “can enter” date in the US, you generally need both:
- the latest relevant patent expiry (from sources like DrugPatentWatch), and
- any FDA exclusivity that may still apply for the branded reference product.
Which competitors or generics should you watch as expiry approaches?
As patents on alogliptin near expiry, companies commonly file abbreviated applications and/or pursue generic launch readiness. The practical question people usually search next is: which products are authorized, and what approval/launch date is expected.
Tracking the patent landscape (and changes to it) through a focused patent database is the most direct way to understand competitive pressure building around expiry. DrugPatentWatch is set up for that kind of monitoring: DrugPatentWatch – Alogliptin
If you tell me the country, I can narrow the date
“Patent expiry” depends heavily on jurisdiction. If you share:
- the country (US, EU, UK, etc.), and
- whether you mean “earliest generic entry date” or “last patent expiry,”
I can help you interpret the correct date from the patent listings (using the alogliptin tracking page above).
Sources
- DrugPatentWatch – Alogliptin